About china pharma holdings inc - CPHI
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
CPHI At a Glance
China Pharma Holdings, Inc.
No.17, Jinpan Road
Haikou, Hainan 570216
| Phone | 86-898-6681-1730 | Revenue | 4.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,187,556.00 | |
| Sector | Health Technology | Employees | 221 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CPHI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.253 |
| Price to Book Ratio | 0.819 |
| Price to Cash Flow Ratio | 35.01 |
| Enterprise Value to EBITDA | -5.086 |
| Enterprise Value to Sales | 2.037 |
| Total Debt to Enterprise Value | 0.426 |
CPHI Efficiency
| Revenue/Employee | 18,752.344 |
| Income Per Employee | -14,423.33 |
| Receivables Turnover | 14.257 |
| Total Asset Turnover | 0.179 |
CPHI Liquidity
| Current Ratio | 0.317 |
| Quick Ratio | 0.097 |
| Cash Ratio | 0.047 |
CPHI Profitability
| Gross Margin | -23.733 |
| Operating Margin | -78.158 |
| Pretax Margin | -76.915 |
| Net Margin | -76.915 |
| Return on Assets | -13.785 |
| Return on Equity | -20.666 |
| Return on Total Capital | -12.022 |
| Return on Invested Capital | -19.706 |
CPHI Capital Structure
| Total Debt to Total Equity | 15.687 |
| Total Debt to Total Capital | 13.56 |
| Total Debt to Total Assets | 11.532 |
| Long-Term Debt to Equity | 0.487 |
| Long-Term Debt to Total Capital | 0.421 |